Myriad Genetics (MYGN) Azione Prezzo
Myriad Genetics Prezzo
Il fatturato è cresciuto a un tasso composto del 11,0% annuo negli ultimi 19 anni, raggiungendo 824,50 Mio. USD. L'utile per azione è diminuito del 17,1% all'anno negli ultimi 11 anni. Il margine netto di Myriad Genetics si attesta al -44,4%, in calo rispetto al -3,9% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 3,00 USD, ovvero il 45,1% sotto il prezzo attuale. Su 14 analisti, 1 valutano il titolo come acquisto — nel complesso un consenso Mantenere.
Myriad Genetics Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Myriad Genetics Azione e analisi azionaria
Domande frequenti sull'azione Myriad Genetics
The business model of Myriad Genetics Inc revolves around providing molecular diagnostic tests and genetic analysis services. As a leading molecular diagnostics company, Myriad Genetics focuses on developing and marketing innovative genetic tests for various medical conditions, including cancer and genetic disorders. With a strong emphasis on research and technology, Myriad Genetics aims to improve patient care and outcomes through personalized medicine. By offering a wide range of genetic testing services, the company strives to empower healthcare providers and individuals with valuable genetic insights, enabling more precise diagnosis, treatment decisions, and proactive healthcare management. Myriad Genetics Inc's business model primarily centers on genetic testing for various medical conditions.
Myriad Genetics Inc is primarily active in the healthcare and biotechnology industries.
The main competitors of Myriad Genetics Inc in the market include companies like Invitae Corporation, Illumina Inc, NeoGenomics Laboratories Inc, and Natera Inc.
Myriad Genetics Inc is a leading molecular diagnostics company based in the United States. Founded in 1991, the company has a rich history and has made significant contributions to the field of genetic testing and personalized medicine. Myriad Genetics Inc specializes in developing and marketing innovative genetic tests, including those for hereditary cancer and rare diseases. With a strong focus on research and development, the company has established itself as a trusted provider of genetic testing services worldwide. Myriad Genetics Inc's commitment to advancing healthcare through genetic insights has made it a prominent player in the industry.
Myriad Genetics Inc has achieved several significant milestones throughout its history. One notable achievement is the development of the BRACAnalysis test, which is a groundbreaking genetic test used to identify individuals with a higher risk of developing hereditary breast and ovarian cancer. This test has revolutionized the field of genetic testing and has had a major impact on cancer prevention and treatment. Additionally, Myriad Genetics Inc has successfully expanded its portfolio to include various genetic tests for other diseases, including prostate cancer and hereditary colon cancer. The company continues to innovate and make strides in the field of genetic testing, solidifying its position as a leader in the industry.
Myriad Genetics Inc is primarily present in various countries and regions worldwide. The company has a global presence, with operations and offices in several key locations. Some of the countries and regions where Myriad Genetics Inc is primarily present include the United States, Canada, Europe (including countries like the United Kingdom, France, Germany, Italy, and Spain), Asia Pacific (including countries like Japan, China, and Australia), and Latin America. This widespread presence allows Myriad Genetics Inc to serve a wide range of customers and collaborate with medical professionals and researchers globally.
Myriad Genetics Inc represents values of innovation, dedication to patients, and commitment to improving healthcare through genetic testing and personalized medicine. With a corporate philosophy centered around advancing precision medicine, Myriad Genetics is focused on developing groundbreaking molecular diagnostic tests that enable early detection and prevention of diseases such as cancer. The company aims to empower healthcare professionals and patients with reliable, actionable genetic information to make informed decisions about treatment and preventative measures. Myriad Genetics' dedication to quality, accuracy, and ethical practices makes it a trusted leader in the field of genetic testing and precision medicine.
Gli analisti fissano attualmente un prezzo obiettivo medio di 4,00 USD per l’azione Myriad Genetics (mediana: 3,00 USD), pari a -27,8 % rispetto all’ultimo prezzo. Il consenso si basa su 14 giudizi di analisti.
14 analisti valutano attualmente l’azione Myriad Genetics: 1 raccomandano l’acquisto, 8 la tenuta e 5 la vendita. Per il 2026 gli analisti si aspettano per Myriad Genetics ricavi pari a 786,05 Mio. USD e un utile per azione di -0,69 USD.
Convertita al tasso di cambio attuale, l’azione Myriad Genetics quota 4,97 EUR (5,46 USD).
L’azione Myriad Genetics (MYGN) è quotata su 9 borse, tra cui: NASDAQ (MYGN), London (0K3W.L), SIX (Zürich) (MYD.SW), XETRA (MYD.DE), Frankfurt (MYD.F), München (MYD.MU), Düsseldorf (MYD.DU), Hamburg (MYD.HM).
The company Myriad Genetics Inc. is a US-American company that specializes in the development and marketing of medical testing procedures and personalized medicine solutions. The business model includes three main divisions: genetic testing, molecular diagnostics, and personalized medicine. In the genetic testing division, Myriad Genetics offers a comprehensive range of genetic tests, including BRCA1 and BRCA2 tests, which are specifically designed to identify the risk of breast cancer in women and men. In addition, the company offers tests for hereditary colon and skin cancer, as well as tests for genetic disorders and hereditary types of cancer. These tests are aimed at providing doctors with a solid basis for making informed decisions, diagnosing accurately, and choosing the best treatment options for their patients. In molecular diagnostics, the company focuses on developing testing procedures specifically designed to identify the genetic basis of certain diseases. Myriad Genetics has developed a wide range of molecular tests that are used in the early detection and treatment of diseases such as breast cancer, colon cancer, and prostate cancer. Personalized medicine reflects the core idea of Myriad Genetics' business model. It involves using a patient's genetics to develop individualized treatment options. The company has developed various technologies tailored to an individual's genetic profile to enable better prediction of the effectiveness of medications and therapies. The goal is to create tailored, targeted treatment methods for patients through personalized medicine and genomic therapies. An important part of Myriad Genetics' business is collaboration with leading researchers, doctors, and medical institutions worldwide. The company has established partnerships with leading oncologists and cancer centers to promote the use of tests and personalized medicine solutions. Additionally, Myriad Genetics has a strong research department that continuously focuses on new technologies and innovative therapies for the treatment of cancer and other serious illnesses. Overall, Myriad Genetics' business model offers a comprehensive range of innovative products and services for the medical community and patients worldwide. The company continuously works to expand and improve its offerings in order to provide the best possible diagnosis and treatment options based on the individual genetic characteristics of each patient.
Il attesa fatturato di Myriad Genetics ammonta a 786,05 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Myriad Genetics ammonta a -64,58 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Myriad Genetics è attualmente -7,89. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Myriad Genetics.
Il rapporto prezzo/fatturato (P/S) di Myriad Genetics è attualmente 0,65. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Myriad Genetics.
Il Quality Score AlleAktien per Myriad Genetics è 2/10.
L'ISIN di Myriad Genetics è US62855J1043. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Myriad Genetics è 897518. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Myriad Genetics è MYGN. Con questo simbolo di borsa vengono negoziate le azioni Myriad Genetics in borsa.
Azione Myriad Genetics
Gruppo di pari di Myriad Genetics
Myriad Genetics Ticker
Myriad Genetics FIGI
Altre metriche e analisi di Myriad Genetics in Deep Dive.
La nostra analisi azionaria dell'azione Myriad Genetics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Myriad Genetics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: